Kaya, Zelal ZuhalTuzuner, Mete BoraŞahin, BetulAkgün, EmelAksungar, FehimeKoca, SebileSerdar, Muhittin2024-07-122024-07-1220221567-20501875-582810.2174/15672050196662201311013342-s2.0-85125725716https://doi.org/10.2174/1567205019666220131101334https://hdl.handle.net/20.500.12415/6965Background: Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss and cognitive impairment. The diagnosis of Alzheimer's disease according to symptomatic events is still a puzzling task. Developing a biomarker-based, low-cost, and high-throughput test, readily applicable in clinical laboratories, dramatically impacts the rapid and reliable detection of the disease. Objective: This study aimed to develop an accurate, sensitive, and reliable screening tool for diagnosing Alzheimer's disease, which can significantly reduce the cost and time of existing methods. Methods: We have employed a MALDI-TOF-MS-based methodology combined with a microaffinity chromatography enrichment approach using affinity capture resins to determine serum kappa (kappa) and lambda (lambda) light chain levels in control and patients with AD. Results: We observed a statistically significant difference in the kappa light chain over lambda light chain (kappa LC/lambda LC) ratios between patients with AD and controls (mean difference -0,409; % 95 CI: -0.547 to -0.269; p<0.001). Our method demonstrated higher sensitivity (100.00%) and specificity (71.43%) for discrimination between AD and controls. Conclusion: We have developed a high-throughput screening test with a novel sample enrichment method for determining kappa LC/kappa LC ratios associated with AD diagnosis. Following further validation, we believe our test has the potential for clinical laboratories.eninfo:eu-repo/semantics/closedAccessAlzheimer's DiseaseMaldi-Tof-MsScreening ToolMicroaffinity ChromatographyAffinity Capture ResinsKappa Light ChainRatioLambda Light Chain RatioArticle93135100957Q28419WOS:000826095800008Q4